NCT00416624 · OUTCOME
Weekly Change in Hemoglobin Levels
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- g/dL
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and Week 4, 7, 10, 13, 16
What was measured
To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule
Analysis population: All patients that were evaluable per protocol and had hemoglobin data at baseline, week 4, 7, 10, 13 or 16.
Groups in this outcome
Epoetin Alfa - 40k Weekly
Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)
Epoetin Alfa - 80k Every 3 Weeks
Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
Epoetin Alfa - 120k Every 3 Weeks
Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
Darbepoetin Alfa - 500 mcg Every 3 Weeks
Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)
| Group | Source count |
|---|---|
| Epoetin Alfa - 40k Weekly | 61 |
| Epoetin Alfa - 80k Every 3 Weeks | 60 |
| Epoetin Alfa - 120k Every 3 Weeks | 58 |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 57 |
Reported measurements
Week 4 Minus Baseline
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 1.0 | 1.26 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 0.6 | 1.02 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 0.7 | 1.21 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 0.4 | 1.21 | Not reported | Not reported | Not reported |
Week 7 Minus Baseline
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 1.7 | 1.28 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 1.0 | 1.58 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 1.1 | 1.25 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 1.5 | 1.59 | Not reported | Not reported | Not reported |
Week 10 Minus Baseline
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 1.7 | 1.39 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 1.2 | 1.42 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 1.2 | 1.37 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 1.5 | 1.44 | Not reported | Not reported | Not reported |
Week 13 Minus Baseline
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 2.1 | 1.27 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 1.2 | 1.51 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 1.3 | 1.32 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 1.6 | 1.65 | Not reported | Not reported | Not reported |
Week 16 Minus Baseline
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 1.7 | 1.67 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 1.2 | 1.64 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 1.6 | 1.44 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 1.9 | 1.41 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 1.26
- value
- 1.0
- group Id
- OG001
- spread
- 1.02
- value
- 0.6
- group Id
- OG002
- spread
- 1.21
- value
- 0.7
- group Id
- OG003
- spread
- 1.21
- value
- 0.4
- title
- Week 4 Minus Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 1.28
- value
- 1.7
- group Id
- OG001
- spread
- 1.58
- value
- 1.0
- group Id
- OG002
- spread
- 1.25
- value
- 1.1
- group Id
- OG003
- spread
- 1.59
- value
- 1.5
- title
- Week 7 Minus Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 1.39
- value
- 1.7
- group Id
- OG001
- spread
- 1.42
- value
- 1.2
- group Id
- OG002
- spread
- 1.37
- value
- 1.2
- group Id
- OG003
- spread
- 1.44
- value
- 1.5
- title
- Week 10 Minus Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 1.27
- value
- 2.1
- group Id
- OG001
- spread
- 1.51
- value
- 1.2
- group Id
- OG002
- spread
- 1.32
- value
- 1.3
- group Id
- OG003
- spread
- 1.65
- value
- 1.6
- title
- Week 13 Minus Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 1.67
- value
- 1.7
- group Id
- OG001
- spread
- 1.64
- value
- 1.2
- group Id
- OG002
- spread
- 1.44
- value
- 1.6
- group Id
- OG003
- spread
- 1.41
- value
- 1.9
- title
- Week 16 Minus Baseline
- denoms
- counts
- group Id
- OG000
- value
- 61
- group Id
- OG001
- value
- 60
- group Id
- OG002
- value
- 58
- group Id
- OG003
- value
- 57
- units
- Participants
- description
- To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule
- dispersion Type
- Standard Deviation
- groups
- description
- Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)
- id
- OG000
- title
- Epoetin Alfa - 40k Weekly
- description
- Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG001
- title
- Epoetin Alfa - 80k Every 3 Weeks
- description
- Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG002
- title
- Epoetin Alfa - 120k Every 3 Weeks
- description
- Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG003
- title
- Darbepoetin Alfa - 500 mcg Every 3 Weeks
- param Type
- MEAN
- population Description
- All patients that were evaluable per protocol and had hemoglobin data at baseline, week 4, 7, 10, 13 or 16.
- reporting Status
- POSTED
- time Frame
- Baseline and Week 4, 7, 10, 13, 16
- title
- Weekly Change in Hemoglobin Levels
- type
- SECONDARY
- unit Of Measure
- g/dL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle